Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Safety and efficacy of total body irradiation, cyclophosphamide, and cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Mori T, Aisa Y, Kato J, Yamane A, Nakazato T, Shigematsu N, Okamoto S.
Am J Hematol. 2012 Apr;87(4):349-53. doi: 10.1002/ajh.23109. Epub 2012 Jan 31.
Related citations
A basis for updating our approach to resistant acute leukemia.
Cunningham I.
Am J Hematol. 2012 Mar;87(3):251-7. doi: 10.1002/ajh.22256. Epub 2012 Jan 28.
Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia.
Yokoyama T, Toki T, Aoki Y, Kanezaki R, Park MJ, Kanno Y, Takahara T, Yamazaki Y, Ito E, Hayashi Y, Nakamura T.
Blood. 2012 Mar 15;119(11):2608-11. Epub 2012 Jan 31.
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.
Walter RB, Appelbaum FR, Estey EH, Bernstein ID.
Blood. 2012 Jan 27. [Epub ahead of print]
CMV-specific cellular therapy for acute myeloid leukemia?
Thomson KJ, Mackinnon S, Peggs KS.
Blood. 2012 Jan 26;119(4):1088-90; author reply 1090-1. No abstract available.
Presence of high-ERG expression is an independent unfavorable prognostic marker in MLL-rearranged childhood myeloid leukemia.
Pigazzi M, Masetti R, Martinolli F, Manara E, Beghin A, Rondelli R, Locatelli F, Fagioli F, Pession A, Basso G.
Blood. 2012 Jan 26;119(4):1086-7; author reply 1087-8. No abstract available.
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.
Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D.
Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26.
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Willer A, Gerss J, König T, Franke D, Kühnel HJ, Henze G, von Stackelberg A, Möricke A, Schrappe M, Boos J, Lanvers-Kaminsky C.
Blood. 2011 Nov 24;118(22):5774-82. Epub 2011 Sep 22.
AU-rich RNA binding proteins in hematopoiesis and leukemogenesis.
Baou M, Norton JD, Murphy JJ.
Blood. 2011 Nov 24;118(22):5732-40. Epub 2011 Sep 13.
Defining the optimal dose of radiation in leukemic patients with extramedullary lesions.
Song JH, Son SH, Lee JH, Chung SM, Jang HS, Choi BO.
BMC Cancer. 2011 Oct 6;11:428.
Risks and benefits of ovarian shielding in female patients undergoing TBI: a decision analysis.
Kanda Y, Sakamoto K, Ashizawa M, Sato M, Terasako K, Kikuchi M, Kimura SI, Okuda S, Kako S, Oshima K.
Bone Marrow Transplant. 2011 Aug;46(8):1145-7. doi: 10.1038/bmt.2010.240. Epub 2010 Oct 11. No abstract available.
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.
Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K; United Kingdom Childhood Leukaemia Working Group and the Dutch Childhood Oncology Group.
Br J Haematol. 2011 Nov;155(3):366-76. doi: 10.1111/j.1365-2141.2011.08851.x. Epub 2011 Sep 9.
Molluscum contagiosum in a patient with adult T-cell leukaemia/lymphoma.
Chen KW, Yang CF, Huang CT, Chiou TJ, Liu CY.
Br J Haematol. 2011 Nov;155(3):286. doi: 10.1111/j.1365-2141.2011.08776.x. Epub 2011 Jun 17. No abstract available.
Near-tetraploid acute myeloid leukaemia.
Wan TS, Ma ES, Chen YT.
Br J Haematol. 2011 Nov;155(3):285. doi: 10.1111/j.1365-2141.2011.08774.x. Epub 2011 Jun 17. No abstract available.
Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis.
Sheen C, Vincent T, Barrett D, Horwitz EM, Hulitt J, Strong E, Grupp SA, Teachey DT.
Br J Haematol. 2011 Nov;155(3):403-7. doi: 10.1111/j.1365-2141.2011.08696.x. Epub 2011 May 9. No abstract available.
De novo acute myeloid leukemia risk factors: A Texas case-control study.
Strom SS, Oum R, Elhor Gbito KY, Garcia-Manero G, Yamamura Y.
Cancer. 2012 Feb 1. doi: 10.1002/cncr.27442. [Epub ahead of print]
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Huang X, Cortes J, Kantarjian H.
Cancer. 2012 Jan 31. doi: 10.1002/cncr.26679. [Epub ahead of print]
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM.
Cancer. 2012 Jan 26. doi: 10.1002/cncr.27429. [Epub ahead of print]
Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy--retrospective analysis of changes over 3 yr in a German hospital.
Böhme A, Atta J, Mousset S, Ehlken B, Shlaen M, Bug G, Serve H, Hoelzer D.
Eur J Haematol. 2012 Jan;88(1):68-77. doi: 10.1111/j.1600-0609.2011.01704.x. Epub 2011 Oct 13.
Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia.
Levinsen M, Shabaneh D, Bohnstedt C, Harila-Saari A, Jonsson OG, Kanerva J, Lindblom A, Lund B, Andersen EW, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO).
Eur J Haematol. 2012 Jan;88(1):78-86. doi: 10.1111/j.1600-0609.2011.01695.x. Epub 2011 Oct 2.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on